Finance

Beta
Lists
2162:HKG
Keymed Biosciences Inc
HK$58.40
-1.10%
(-0.65) 1D
Jun 5, 4:09:10 PM GMT+8  ·   HKD
All symbols
SymbolPriceChange% Change
Generating top insights for 2162...
Open
HK$60.95
High
HK$62.70
Low
HK$57.85
Mkt. cap
17.61B
Avg. vol.
1.93M
Volume
3.56M
52-wk high
HK$81.85
52-wk low
HK$43.80
EPS
-HK$2.21
No. of employees
2K
Open
HK$60.95
High
HK$62.70
Low
HK$57.85
Mkt. cap
17.61B
Avg. vol.
1.93M
Volume
3.56M
52-wk high
HK$81.85
52-wk low
HK$43.80
EPS
-HK$2.21
No. of employees
2K
Analyst outlook
Analyst Ratings
Based on 5 analysts giving stock ratings to 2162 in the past 3 months
Strong Buy
Buy
5
Hold
0
Sell
0
12 month forecast
Based on 5 Wall Street analysts offering 12 month price targets for 2162 in the last 3 months.
Highest
Current HK$58.40
HK$97.00 (+66.10%)
Average
HK$88.58 (+51.68%)
Lowest
HK$78.00 (+33.56%)
News stories
From sources across the web
About Keymed Biosciences Inc
CEOBo Chen
Employees1.62K
FoundedSep 2016
Headquarters-
SectorBiotechnology
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
249.38M
249.38M
108.78M
108.78M
Cost of goods sold
16.74M
16.74M
27.89M
27.89M
Cost of revenue
16.74M
16.74M
27.89M
27.89M
Research and development expenses
180.01M
180.01M
181.76M
181.76M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
113.42M
113.42M
138.68M
138.68M
Operating expense
299.80M
299.80M
329.25M
329.25M
Total operating expenses
316.54M
316.54M
357.14M
357.14M
Operating income
-67.17M
-67.17M
-248.36M
-248.36M
Other non operating income
17.72M
17.72M
11.36M
11.36M
EBT including unusual items
-37.83M
-37.83M
-222.53M
-222.53M
EBT excluding unusual items
-37.95M
-37.95M
-237.85M
-237.85M
Income tax expense
1.57M
1.57M
-630.50K
-630.50K
Effective tax rate
-4.14%
-4.14%
0.28%
0.28%
Other operating expenses
6.07M
6.07M
8.82M
8.82M
Net income
-39.42M
-39.42M
-221.90M
-221.90M
Net profit margin
-15.81%
-15.81%
-203.99%
-203.99%
Earnings per share
-
-
-
-
Interest and investment income
19.93M
19.93M
15.16M
15.16M
Interest expense
-3.73M
-3.73M
-4.72M
-4.72M
Net interest expenses
16.20M
16.20M
10.44M
10.44M
Depreciation and amortization charges
-
-
-
-
EBITDA
-46.98M
-46.98M
-227.66M
-227.66M
Gain or loss from assets sale
-
-
-15.50K
-15.50K
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more